The Top 5 Analyst Questions From DaVita’s Q2 Earnings Call
DaVita’s second quarter results surpassed Wall Street’s revenue and adjusted profit expectations, but the market response was notably negative. Management attributed this to a mix of operational and industry-specific challenges, including flat treatment volumes and sequential declines in revenue per treatment, primarily due to a less favorable commercial mix and reduced revenue from phosphate binders. CEO Javier Rodriguez emphasized, “Our growth is mainly performance clinical—that expands life,
Yahoo22 days agoDVA
S&P 500 Earnings Are So Good Investors Are Starting to Worry
(Bloomberg) -- The latest reason to worry about the stock market is quite the doozy: Earnings growth has been too strong. Most Read from BloombergPhoebe Gates Knew Phia Shopping App Took Credit for Sales It Didn’t DriveTrump Weighs Call for Capital Gains Tax Cuts as Midterm BoostTata Sons Chairman to Step Down, Deepening Leadership TurmoilFive Takeaways From Zuckerberg’s 6,500-Word Manifesto on AIEpstein Victim Files Cleared for Release Over Maxwell’s ProtestAs the latest reporting season nears
Yahoo23 days agoDVA
DaVita Community Care Report 2025: Creating a Culture of Belonging for All
NORTHAMPTON, MA / ACCESS Newswire / August 12, 2026 /Working Together, Working for Better At DaVita, people are the foundation of our community and the driving force behind our pursuit of a healthier tomorrow for all. Rooted in our identity as a community ...
Yahoo23 days agoDVA
DaVita (DVA) Q2 2026 Earnings Call Transcript
Mortality gains drove treatment growth despite payor mix headwinds.
Yahoo23 days agoDVA
Are Wall Street Analysts Bullish on DaVita Stock?
Though DaVita has outpaced the broader market over the past year, Wall Street analysts maintain a cautiously optimistic outlook on the stock’s prospects.
Yahoo24 days agoDVA
DaVita (DVA) Stock Still Looks Undervalued Despite A Q2 Earnings Beat
DaVita stock has climbed 69.6% over the past three years. After a recent pullback and a strong value score, the current price still raises questions about how much upside investors are actually paying for. Over the past 3 years, DaVita has returned 69.6%, which puts recent share price weakness in the context of a longer period of strong gains. Support for the valuation can come from expectations that DaVita benefits from growing demand for integrated kidney and metabolic care. Execution...
Yahoo27 days agoDVA
TD Cowen Upgrades DaVita (DVA)
Fintel27 days agoDVA
TD Cowen Upgrades DaVita to Buy, Lowers Price Target to $220
TD Cowen analyst Ryan Langston upgrades DaVita (NYSE:DVA) from Hold to Buy and lowers the price target from $201 to $220.
Benzinga28 days agoDVA